Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2007

View Archived Issues

CP-4126 well tolerated in solid tumor patients

Orphan Europe seeks EMEA approval of Vedrop for vitamin E deficiencies

Desvenlafaxine improves hot flushes, mood in postmenopausal women

Alcon submits amendment to NDA for Patanase

Lupin acquires majority stake in Kyowa

Wyeth and Zealand begin phase I trials on ZP-1609

FDA grants orphan drug status to recombinant fibrinogen

Enrollment complete for phase III clinical trial of pravastatin combination therapy

FDA denies approval of CX-717 clinical trials for ADHD

Affymax begins patient dosing in phase III trial of Hematide

Partial response rate reported in Davant phase II trial for colorectal cancer

Momenta evaluates M-118 in broad ACS clinical program

NS-1738, an allosteric modulator of alpha7 nAChRs improves short- and long-term memory in vivo

Phase III study of Gattex demonstrates clinical benefits

Series B financing by Metastatix to support cancer drug clinical trials

SpirH begins phase II study and opens enrollment for worldwide clinic participation

NPS sells mGluR collaboration assets to AstraZeneca

Novel NO donor shows potential in inflammatory skin conditions

Doribax approved by FDA for the treatment of cIAI and cUTI

Gilead submits marketing applications for Viread in U.S. and E.U.

NDA for Ampligen submitted by Hemispherx Biopharma

FDA approves use of Lexiva with reduced dose of ritonavir

Clinical data on PEP-005 topical gel for skin cancers presented

Recent Janssen and Astellas patents report novel therapeutic agents for thrombotic disorders

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents describe new treatment options for cardiovascular disorders

The ACAT inhibitor KY-382 shows antiatherosclerotic effects in rabbits

Tamoxifen for the treatment of acute mania / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...